Clinical Trials Logo

Filter by:
NCT ID: NCT05104398 Completed - COVID-19 Clinical Trials

Hemoperfusion With the Efferon CT Extracorporeal Adsorbers in Patients With Severe Covid-19

Start date: October 1, 2020
Phase:
Study type: Observational

Direct extracorporeal removal of inflammatory mediators with various adsorbents has been suggested as a novel treatment modality for COVID-19 patients. Study determined safety, feasibility and effectiveness of clinical use of a hemoperfusion (HP) with a novel styrene- divinylbenzene copolymer (SDC) adsorbers to remove pro-inflammatory molecules from the bloodstream of COVID-19 patients.

NCT ID: NCT05095545 Completed - Influenza Clinical Trials

Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza

Start date: November 13, 2017
Phase: Phase 2
Study type: Interventional

Assessment of the effect reached with the different doses of AV5080 on the duration and severity of influenza symptoms based on the incidence of their resolution within 96 hours from study treatment initiation compared to Placebo. The absence of influenza symptoms or their reduction to mild severity for at least 24 hours indicates the resolution of influenza.

NCT ID: NCT05092698 Completed - SARS-CoV2 Infection Clinical Trials

The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19

COVID-VIT
Start date: May 1, 2020
Phase: N/A
Study type: Interventional

Despite the successful treatment of patients with moderate coronavirus disease 2019 (COVID-19), outcomes for patients with severe disease remain unsatisfactory. In this category of patients, the course of the disease is complicated by the development of acute respiratory distress syndrome (ARDS) and the need for mechanical ventilation in the intensive care unit (ICU). Mortality in this category of patients reaches 85%. The lack of effective treatment for COVID-19 has prompted scientists to look for new strategies to reduce the incidence and severity of COVID-19, disease progression, and mortality. Disease severity and mortality rates due to COVID-19 infection are greater in the elderly and chronically ill patients, populations at high risk for vitamin D deficiency. Vitamin D plays an important role in immune function and inflammation. A number of experimental studies have shown that stimulation of vitamin D receptors can improve the course of ARDS due to inhibition of the hyperimmune inflammatory response, regulation of the renin-angiotensin system, modulation of neutrophil activity, maintenance of the integrity of the pulmonary epithelial barrier and stimulation of epithelial repair, as well as by reducing hypercoagulation. Several studies on ICU patients have reported that low vitamin D (25(OH)D) concentrations are associated with a higher risk of negative outcomes such as death, organ failure, prolonged mechanical ventilation, a higher rate of ventilation-associated pneumonia, and sepsis. While the available evidence to-date, from largely poor-quality observational studies, may be viewed as showing a trend for an association between low serum 25(OH)D levels and COVID-19 related health outcomes, this relationship was not found to be statistically significant. Calcifediol supplementation may have a protective effect on COVID-19 related ICU admissions.

NCT ID: NCT05091515 Completed - Overheating Clinical Trials

Thermoregulatory Reactions of Medical Workers Who Use Personal Protective Equipment From Biological Hazards

Start date: March 29, 2021
Phase:
Study type: Observational

This research will provide data on thermal condition, functional status and working conditions of medical workers who use personal protective equipment from biological hazards. Acquired data will be used to define acceptable period of use for these protective costumes.

NCT ID: NCT05089123 Completed - Influenza Clinical Trials

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

Start date: March 3, 2020
Phase: Phase 3
Study type: Interventional

This trial by its design was a prospective, multicenter, double blind, randomized comparative clinical trial of the IIIb-IV phase which was carried out in parallel groups of volunteers over the age of 60

NCT ID: NCT05083039 Completed - Clinical trials for Coronavirus Infections

Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19

Start date: May 14, 2020
Phase:
Study type: Observational

Observational program, double-blind, placebo-controlled to study the preventive efficacy of the BiVac polio (Oral polio vaccine, divalent, live attenuated of types 1 and 3 vaccine against the incidence of acute respiratory infections, including COVID-19

NCT ID: NCT05076448 Completed - Clinical trials for May-Thurner Syndrome

The Efficacy and Safety of Interventions on the Pelvic Veins in Pelvic Venous Disorders

ESIPV
Start date: September 30, 2014
Phase:
Study type: Observational

This study includes a retrospective and prospective study will enroll patients with pelvic venous disorders who have undergone pelvic vein surgery and endovascular interventions. Three groups of patients will be formed. The first will include patients who underwent open retroperitoneal resection of the gonadal veins and endoscopic trans- and retroperitoneal resection of the gonadal veins. The second group will include patients who underwent embolization of the gonadal veins with coils, the third - patients who underwent stenting of the common iliac veins, or stenting of the iliac veins in combination with embolization of the gonadic veins with coils. Evaluation of the effectiveness and safety of interventions on the pelvic veins will be carried out by assessing the effect of the intervention on pelvic pain, morphological and functional state of the pelvic veins. The assessment of the safety of interventions on the pelvic veins will be carried out by assessing the severity of post-procedural pain, the frequency of complications of operations on the pelvic veins, and complications of anesthesia. In addition, the duration of pelvic vein interventions will be compared with the length of time the patient is in hospital. Based on the data obtained, an algorithm will be proposed for determining the choice of the method of interventions on the pelvic veins in patients with pelvic venous disorders.

NCT ID: NCT05074888 Completed - Clinical trials for Post-acute COVID-19 Syndrome

Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.

Start date: October 15, 2021
Phase: Phase 3
Study type: Interventional

The multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial. The objective of this study is to evaluate the efficacy and safety of Prospekta in the treatment of asthenia in patients after the coronavirus infectious disease (COVID-19).

NCT ID: NCT05070819 Completed - Cardiac Disease Clinical Trials

Atrial Natriuretic Peptide in Assessing Fluid Status

Start date: September 23, 2021
Phase: N/A
Study type: Interventional

Biomarkers can play a significant role in fluid status assessment intraoperatively.

NCT ID: NCT05070273 Completed - Healthy Volunteers Clinical Trials

Safety and Feasibility of St. Mark's Electrode for the Hypoglossal Nerve and Cortico-lingual Pathway Study

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

The possibility of registering the M-response and the motor evoked potential (MEP) from the muscles of the tongue by using the St. Mark's electrode will be evaluated. The safety of method will be confirmed. Registered parameters will be compared with other known methods and comparative effectiveness of proposed method will be determined. The study will involve healthy volunteers without clinical symptoms of hypoglossal nerve and cortico-lingual pathway lesions and without surgical interventions in the tongue .The volunteers will be examined once for the parameters of the amplitude and latency of the M-response and MEP, as well as the difference between these indicators at different sides of the examination during nerve conduction study (NCS) and transcranial magnetic stimulation (TMS) of the hypoglossal nerve and the cortico-lingual pathway.